Tlwm Purchases New Stake in Boston Scientific Co. (NYSE:BSX)

Tlwm acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 13,538 shares of the medical equipment provider’s stock, valued at approximately $927,000.

A number of other institutional investors have also recently bought and sold shares of BSX. Vanguard Group Inc. grew its stake in Boston Scientific by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 125,449,802 shares of the medical equipment provider’s stock valued at $7,252,253,000 after purchasing an additional 1,681,454 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after purchasing an additional 2,336,348 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of Boston Scientific by 1.5% during the 4th quarter. Primecap Management Co. CA now owns 37,905,659 shares of the medical equipment provider’s stock valued at $2,191,326,000 after purchasing an additional 550,490 shares in the last quarter. Morgan Stanley boosted its holdings in Boston Scientific by 2.3% in the third quarter. Morgan Stanley now owns 21,200,339 shares of the medical equipment provider’s stock worth $1,119,378,000 after purchasing an additional 481,891 shares in the last quarter. Finally, Norges Bank bought a new stake in Boston Scientific in the fourth quarter worth $930,626,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

NYSE:BSX traded down $0.10 during trading hours on Thursday, reaching $77.00. The company had a trading volume of 4,196,078 shares, compared to its average volume of 6,303,551. Boston Scientific Co. has a one year low of $48.35 and a one year high of $77.99. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The stock has a 50-day moving average of $74.46 and a two-hundred day moving average of $67.29. The firm has a market capitalization of $112.97 billion, a PE ratio of 64.62, a PEG ratio of 2.67 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. Analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price target on shares of Boston Scientific in a research report on Tuesday, June 18th. Robert W. Baird upped their target price on Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Monday. Argus upped their price objective on shares of Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Finally, Wells Fargo & Company lifted their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $76.70.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 17,587 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,620,617. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the sale, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,620,617. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,627 shares of company stock worth $5,937,353. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.